Objective: To determine the prevalence and pathological characteristics of the prostate cancer in our institution's TRUS-guided prostate biopsied patients. Patients and method: The age, the PSA level and the pathological data were collected and analyzed by means of Excel 2010®. Concerned patients were those who had consecutively undergone a TRUS-guided prostate biopsy between October 17, 2013 and July 31, 2021. Results: Among 138 patients whose age ranged from 42 to 96 years (mean=65.7years),

more »

... or 58.7% had a PCa. 97,5% of those PCa were in patients with PSA>30ng/mL whereas 40.2% of them were in patients with PSA<30ng/mL (p=0.000). The age discrepancy between the PCa patients and the non PCa patients was not significant (p = 0.291). The percentage of positive cores was significantly higher in the PCa patients with PSA>30ng/mL than in the PCa patients with PSA<20ng/mL (p=0.000 for PSA<10ng/mL and p=0.001 for PSA<20ng/mL). 74,2% of the PCa with a GS>7 had a PSA>30ng/mL whereas 50% of the PCa with a GS 6 had a PSA<10ng/mL (p=0.004). 76, 2% of the PCa with PSA>30ng/mL belonged to the ISUP grade group 5 whereas 50% of the PCa with PSA<10ng/mL belonged to the ISUP grade group 1 (p=0.003). The GS and the percentage of positive cores increased together and that interdependent increment was significant between GS 6 and 7 (p=0.005), 6 and >7 (p=0.000), 7 and >7 (p=0.013). The percentage of positive cores also increased as the ISUP grade group was rising and again the interdependent increment was significant between the ISUP grade group 1 and 3 (p=0.001), 1 and 4 (p=0.000), 1 and 5 (p=0.000), 2 and 5 (p=0.006). Conclusion: The prevalence of the PCa was 58.7% among the 138 biopsied patients. It was 2.4 times higher in the patients with PSA>30ng/mL (95.7%) than in the patients with PSA<30ng/mL (40.2%). The majority of the PCa patients (54.3%) had a PSA>30ng/mL and presented a more elevated Gleason score, a more elevated ISUP grade group and a more elevated percentage of .......